PH12016501359A1 - Treatment of human immunodeficiency virus/acquired immunodeficiency syndrome - Google Patents

Treatment of human immunodeficiency virus/acquired immunodeficiency syndrome

Info

Publication number
PH12016501359A1
PH12016501359A1 PH12016501359A PH12016501359A PH12016501359A1 PH 12016501359 A1 PH12016501359 A1 PH 12016501359A1 PH 12016501359 A PH12016501359 A PH 12016501359A PH 12016501359 A PH12016501359 A PH 12016501359A PH 12016501359 A1 PH12016501359 A1 PH 12016501359A1
Authority
PH
Philippines
Prior art keywords
treatment
virus
viral
human immunodeficiency
immunodeficiency virus
Prior art date
Application number
PH12016501359A
Other languages
English (en)
Inventor
Har-Noy Michael
Original Assignee
Immunovative Therapies Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunovative Therapies Ltd filed Critical Immunovative Therapies Ltd
Publication of PH12016501359A1 publication Critical patent/PH12016501359A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/46—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PH12016501359A 2014-01-08 2016-07-11 Treatment of human immunodeficiency virus/acquired immunodeficiency syndrome PH12016501359A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461924936P 2014-01-08 2014-01-08
PCT/US2015/010658 WO2015105999A1 (en) 2014-01-08 2015-01-08 Treatment of human immunodeficiency virus/acquired immunodeficiency syndrome

Publications (1)

Publication Number Publication Date
PH12016501359A1 true PH12016501359A1 (en) 2016-08-22

Family

ID=53494410

Family Applications (1)

Application Number Title Priority Date Filing Date
PH12016501359A PH12016501359A1 (en) 2014-01-08 2016-07-11 Treatment of human immunodeficiency virus/acquired immunodeficiency syndrome

Country Status (12)

Country Link
US (3) US10272143B2 (2)
EP (1) EP3091990B1 (2)
JP (1) JP6557240B2 (2)
KR (1) KR102503400B1 (2)
CN (1) CN105899219B (2)
AU (1) AU2015204770B2 (2)
BR (1) BR112016015736B1 (2)
CA (1) CA2936086C (2)
IL (1) IL246643B (2)
PH (1) PH12016501359A1 (2)
SG (2) SG11201605440TA (2)
WO (1) WO2015105999A1 (2)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150305983A1 (en) * 2009-11-20 2015-10-29 The University Of Versailles Saint-Quentin-En- Yvelines Quadruple therapy useful for treating persons afflicted with the human immunodeficiency virus (hiv)
US20190069528A1 (en) * 2016-03-21 2019-03-07 The George Washington University Engineered human hookworms as a novel biodelivery system for vaccines and biologicals
US20190085086A1 (en) * 2017-09-18 2019-03-21 Cytodyn Inc. Screening methods for identifying and treating hiv-1 infected patient sub-populations suitable for long term anti-ccr5 agent therapy
USD1001795S1 (en) 2019-10-01 2023-10-17 Microsoft Corporation Computing device

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020022034A1 (en) * 1997-09-15 2002-02-21 Julianna Lisziewicz Therapeutic DNA vaccination
CN1349408A (zh) 1999-05-04 2002-05-15 先灵公司 聚乙二醇化干扰素α－CCR5拮抗剂联合HIV疗法
US6579521B2 (en) 2000-10-20 2003-06-17 Chiron Corporation Methods of therapy for HIV infection
US7435592B2 (en) 2003-05-13 2008-10-14 Immunovative Therapies, Ltd. Compositions for allogeneic cell therapy
US7402431B2 (en) 2004-03-01 2008-07-22 Immunovative Therapies, Ltd. T-cell therapy formulation
US20110142887A1 (en) * 2009-12-15 2011-06-16 Immunovative Therapies Ltd. Methods and compositions for liquidation of tumors
KR20070019635A (ko) * 2003-08-28 2007-02-15 더 임뮨 리스판스 코포레이션 면역원성 ｈｉｖ 조성물 및 이와 관련된 방법
AU2004269379A1 (en) 2003-08-28 2005-03-10 The Immune Response Corporation Immunogenic HIV compositions and related methods
EP2573166B1 (en) * 2004-02-26 2016-05-11 Immunovative Therapies, Ltd. Methods for preparing T-cells for cell therapy
HUE035726T2 (en) 2004-03-01 2018-05-28 Immunovative Therapies Ltd Cell therapy formulation method and composition
US8043619B2 (en) * 2004-10-08 2011-10-25 Yaron Ilan Methods and uses of leptin in immune modulation
US20120128656A1 (en) 2008-05-02 2012-05-24 Immunovative Therapies, Ltd. Vaccine compositions and methods
US9695397B2 (en) * 2008-10-01 2017-07-04 Immunovative Therapies Ltd. Th1 vaccination priming for active immunotherapy
WO2010051521A1 (en) 2008-10-31 2010-05-06 Lentigen Corporation Cell therapy product for the treatment of hiv infection
WO2011077100A1 (en) * 2009-12-24 2011-06-30 Cipla Limited Antiretroviral composition
SG184188A1 (en) * 2010-03-26 2012-10-30 Glaxosmithkline Biolog Sa Hiv vaccine
CN103002915B (zh) 2010-04-13 2015-09-23 免疫创新治疗有限公司 抑制Treg细胞的方法和组合物
WO2011130247A2 (en) 2010-04-14 2011-10-20 The Penn State Research Foundation Strategies for the transgenic manipulation of filamentous fungi

Also Published As

Publication number Publication date
EP3091990A4 (en) 2017-10-04
SG10201908048QA (en) 2019-10-30
JP6557240B2 (ja) 2019-08-07
US20180200348A1 (en) 2018-07-19
CN105899219B (zh) 2021-08-13
AU2015204770A1 (en) 2016-08-18
EP3091990A1 (en) 2016-11-16
CA2936086A1 (en) 2015-07-16
BR112016015736A2 (2) 2017-08-08
IL246643A0 (en) 2016-08-31
CN105899219A (zh) 2016-08-24
US20200368334A1 (en) 2020-11-26
EP3091990B1 (en) 2021-05-12
KR20160124096A (ko) 2016-10-26
JP2017502058A (ja) 2017-01-19
US10272143B2 (en) 2019-04-30
SG11201605440TA (en) 2016-08-30
CA2936086C (en) 2024-02-27
BR112016015736B1 (pt) 2022-01-04
US10729754B2 (en) 2020-08-04
WO2015105999A1 (en) 2015-07-16
AU2015204770B2 (en) 2020-07-02
IL246643B (en) 2020-02-27
US20150190488A1 (en) 2015-07-09
KR102503400B1 (ko) 2023-02-23

Similar Documents

Publication Publication Date Title
MX2020005187A (es) Compuestos y composiciones farmaceuticas antivirales, asi como metodos de uso de los mismos.
MX376190B (es) PARTÍCULAS DE rAAV QUE CODIFICAN miR-708 Y USOS DEL MISMO.
PH12018501281A1 (en) Human immunodeficiency virus neutralizing antibodies
PH12019501010A1 (en) Arginase inhibitor combination therapies
MY187540A (en) Compounds active towards bromodomains
PH12017500803A1 (en) Anti-pd-1 antibodies
PH12017500965A1 (en) Myostatin or activin antagonists for the treatment of sarcopenia
MX386613B (es) El uso de un péptido timosina alfa y un inhibidor de pd-1 para el tratamiento de cáncer o una metástasis de este en un sujeto.
MX2021008113A (es) Composiciones farmaceuticas que comprenden un antagonista de il-4r para usarse en el tratamiento del asma.
PE20180260A1 (es) Metodos y kits para tratar la depresion
MX2021007651A (es) Inhibidores de ezh2 para tratar linfomas.
BR112017000464A2 (pt) células gama delta t e uso das mesmas
ZA202503388B (en) Semaglutide in medical therapy
NZ708537A (en) Method for the preparation of human albumin with reduced level of dissolved oxygen
EA202190927A1 (ru) Иммуноаблативные виды терапии
PH12016501359A1 (en) Treatment of human immunodeficiency virus/acquired immunodeficiency syndrome
MX388503B (es) Uso de anticuerpos antagonistas del receptor de glucagon en el tratamiento de diabétes tipo 1.
MX2022013912A (es) Procedimientos novedosos para inducir una respuesta inmunitaria.
PH12019550033A1 (en) Treatment of non-hodgkin lymphoma using lilotomab and 177lu-lilotomab satetraxetan
MX2017007027A (es) Antagonista de a2a de dosis baja para el tratamiento de tdah y la enfermedad de parkinson.
PH12017500820A1 (en) Combination long acting compositions and methods for hepatitis c
PH12017500816A1 (en) Long acting pharmaceutical compositions for hepatitis c
TW201613939A (en) Imidazopyridine macrocycles as inhibitors of human immunodeficiency virus replication
MX2017016533A (es) Metodo para tratar glomeruloesclerosis focal y segmentaria primaria.
Near The sentence should have been given as,“If the VGPRs were included with the complete responders (CRnCR), the response rate rose to 56% for VTD and 35% for TD (P. 001; Table 2). Median time to first response (PR or better) was